| Abstract | Acinetobacter baumannii is a major cause of healthcare-associated infections worldwide with high morbidity and mortality. The clinical treatment of A. baumannii infections has become increasingly difficult because of the rapid emerging of multidrug and extremely drug resistant strains. Thus, there is an urgent need for the development of novel intervention strategies to combat this multidrug-resistant pathogen. Vaccine is one of the most effective medical measures for infection control and is likely to overcome the development of multidrug resistance by A. baumannii. Here we discussed the recent advances and potential challenges in development of A. baumannii vaccines with a focus on the 3 most important steps in the preclinical vaccine development: antigen selection, immune correlates of protection, and animal models for efficacy evaluation. |
|---|
